This site requires Flash 8.

If you are seeing this message it indicates that Flash has not been properly installed. You can install Flash by visiting the Adobe website or clicking here.

Products Overview

CINRYZE ® 

- HAE Overview

- CinryzeSolutions®

- Package Insert (HTML | PDF)

- MSDS (PDF)

VANCOCIN®

- C. difficile Overview

- Patient Assistance Program

- Package Insert (HTML | PDF)

- MSDS (PDF)

CINRYZE® (C1 Esterase Inhibitor [Human])

See how CINRYZE® (C1 esterase inhibitor [human]) represents a solution to HAE, a rare and debilitating disease

Learn more about the function of C1 Esterase Inhibitor, and increasing plasma levels of C1 inhibitor activity with  CINRYZE®  (C1 Esterase Inhibitor [Human]). View the CINRYZE® Full Prescribing Information.

The following information is intended for use by viewers in the United States.

CINRYZE ® (C1 Esterase Inhibitor [Human]) is an FDA-approved C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).  CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

CINRYZE® (C1 Esterase Inhibitor [Human]) is an injectable medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE).
 
Important Information About CINRYZE®
Before starting CINRYZE, please read the Patient Labeling carefully and each time you get a refill.

This information does not include all of the important information about CINRYZE.  If you have questions after reading this, ask your healthcare provider.
 
Important Risk Information
You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.
 
Tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or planning to become pregnant.  It is not known if CINRYZE can harm your unborn baby.
  • Are breastfeeding or plan to breastfeed.  It is not known if CINRYZE passes into your milk and if it can harm your baby.
  • Or have a history of blood clotting problems. Blood clots have occurred in patients receiving CINRYZE.

Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.
 
Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, or hives.
 
Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. In clinical studies, the most common side effects seen with CINRYZE were upper respiratory tract infection, sinusitis, rash and headache.  These are not all the possible side effects of CINRYZE.  Tell your healthcare provider about any side effect that bothers you or that does not go away.  You can also report side effects to the FDA at 1-800-FDA-1088.
 
Do not use CINRYZE for a condition for which it is not prescribed.  Do not share CINRYZE with other people, even if they have the same symptoms that you have.